OTC:ONPPF Oncopeptides AB (publ) (ONPPF) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free ONPPF Stock Alerts $0.60 0.00 (0.00%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$0.60▼$0.6050-Day Range$0.60▼$0.6052-Week Range$0.60▼$0.60VolumeN/AAverage Volume2,250 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartStock AnalysisAnalyst ForecastsChart Get Oncopeptides AB (publ) alerts: Email Address Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Oncopeptides AB (publ)Oncopeptides AB (publ), a biotech company, engages in the commercialization, and research and development of treatments for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is melflufen, a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, SwedenRead More ONPPF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONPPF Stock News HeadlinesMarch 6, 2024 | gurufocus.comOncopeptides AB (publ) - Special Call TranscriptMarch 6, 2024 | gurufocus.comOncopeptides AB (publ) To Present Updated Ocean Results Call TranscriptMay 2, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.November 25, 2022 | prnewswire.comOncopeptides enters into a renewed loan facility agreement of up to €30 million with the European Investment BankNovember 11, 2022 | finance.yahoo.comOncopeptides' Pepaxti has been granted marketing authorization in the UKNovember 9, 2022 | finance.yahoo.comOncopeptides announces the market potential for Pepaxti in EuropeNovember 9, 2022 | finance.yahoo.comOncopeptides publishes Q3 report 2022October 26, 2022 | finance.yahoo.comOncopeptides phase 3 LIGHTHOUSE study further confirms clinical benefit of melflufenMay 2, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.October 20, 2022 | finance.yahoo.comIssue and re-purchase of class C shares for shareholder program and incentive programOctober 5, 2022 | finanznachrichten.deOncopeptides AB: Oncopeptides starts commercialization of Pepaxti in Europe - Germany first marketOctober 3, 2022 | finance.yahoo.comOncopeptides starts commercialization of Pepaxti in Europe - Germany first marketSeptember 23, 2022 | finance.yahoo.comSwedish Biotech’s Cancer Drug Fails With FDA AdvisersSeptember 23, 2022 | finance.yahoo.comOncopeptides provides an update from the meeting with FDAs advisory committee ODACSeptember 23, 2022 | finance.yahoo.comBulletin from an Extra Ordinary General meeting in Oncopeptides AB (publ)September 20, 2022 | finance.yahoo.comBriefing Book for ODAC meeting on benefit/risk profile of Pepaxto now publishedSeptember 19, 2022 | reuters.comONCO.ST - Oncopeptides AB | Stock Price & Latest News | ReutersSeptember 7, 2022 | finance.yahoo.comOncopeptides receives 5 MSEK grant for NK-cell engager project in multiple myelomaAugust 18, 2022 | finance.yahoo.comEuropean Commission approves Oncopeptides' Pepaxti for the treatment of patients with relapsed refractory multiple myelomaAugust 13, 2022 | seekingalpha.comOncopeptides AB GAAP EPS of -SEK0.79, revenue of SEK8.8MAugust 11, 2022 | finance.yahoo.comOncopeptides publishes Q2 report 2022February 17, 2022 | finance.yahoo.comOncopeptides publishes year-end report 2021February 14, 2022 | finance.yahoo.comInvitation to presentation of 2021 year-end resultsJanuary 21, 2022 | finance.yahoo.comOncopeptides rescinds voluntary withdrawal of Pepaxto in the US - no intent to market in the US at this timeJanuary 13, 2022 | finance.yahoo.comOncopeptides phase 3 OCEAN study published in the Lancet HaematologyJanuary 5, 2022 | prnewswire.comOncopeptides announces year-end cash 2021December 10, 2021 | finance.yahoo.comOncopeptides presents new melflufen data at the Annual American Society of Hematology Meeting ASHSee More Headlines Receive ONPPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncopeptides AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTC SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTC:ONPPF CUSIPN/A CIKN/A Webwww.oncopeptides.se Phone46 86 15 20 40FaxN/AEmployees57Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesProf. Rolf Larsson M.D.Ph.D., FounderProf. Rolf Lewensohn M.D.Ph.D., FounderDr. Joachim Gullbo M.D.MSc Pharm, Ph.D., FounderDr. Kristina Luthman Ph.D.FounderProf. Hans Ehrsson M.D.FounderMr. Peter Nygren (Age 65)Founder Mr. Henrik Bergentoft (Age 50)Chief Financial Officer Ms. Eva Nordström M.Sc. (Age 54)MSc Pharm, COO & Deputy MD Ms. Sara Svardgren (Age 45)Head of Human Resources Mr. Rein Piir B.Sc. (Age 66)Senior Advisor More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors ONPPF Stock Analysis - Frequently Asked Questions Should I buy or sell Oncopeptides AB (publ) stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oncopeptides AB (publ) in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ONPPF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ONPPF, but not buy additional shares or sell existing shares. View ONPPF analyst ratings or view top-rated stocks. How have ONPPF shares performed in 2024? Oncopeptides AB (publ)'s stock was trading at $0.60 on January 1st, 2024. Since then, ONPPF shares have increased by 0.0% and is now trading at $0.60. View the best growth stocks for 2024 here. How do I buy shares of Oncopeptides AB (publ)? Shares of ONPPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTC:ONPPF) was last updated on 5/2/2024 by MarketBeat.com Staff From Our Partners😱 This phenomenon is smashing regular market gainsMillPubBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsYour bank is lying to you.MyBankTrackerDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncopeptides AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
